1. 1302 Outcome of elderly patients suffering from solid tumor and admitted to Intensive Care Unit (ICU). (September 2015) Authors: Auclin, E.; Oudard, S.; Guerot, E.; Thibault, C.; Klein, E.; Combe, P.; Hauw-Berlemont, C.; Diehl, J.L.; Fagon, J.Y.; Taieb, J.; Aissaoui, N. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S188 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 2145 Masitinib plus FOLFIRI for second-line treatment of metastatic colorectal cancer: 2-year follow-up of phase open label trial. (September 2015) Authors: Taieb, J.; Borg, C.; Lecomte, T.; Lepere, C.; Chatellier, T.; Smith, D.; Dubreuil, P; Mansfield, C.; Moussy, A.; Hermine, O. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S381 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 2167 Microsatellite status predicts BRAF V600E and KRAS exon 2 mutations prognostic value in stage III colon cancers (CC) patients treated with adjuvant FOLFOX +/- cetuximab. A post-hoc analysis of the PETACC8 trial. (September 2015) Authors: Taieb, J.; Zaanan, A.; Malicot, K. Le; Julie, C.; Blons, H.; Mineur, L.; Tabernero, J.; Mini, E.; Folprecht, G.; Laethem, J.L. Van; Lepage, C.; Emile, J.F.; Laurent-Puig, P. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S389 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 2349 Phase 1b/2 study results for masitinib plus irinotecan in second-line treatment of esophagogastric adenocarcinoma. (September 2015) Authors: Zaanan, A.; Bennouna, J.; Hiret, S.; Douillard, J.Y.; Bouche, O.; Tougeron, D.; Lecomte, T.; Ezenfis, J.; Lepere, C.; Mansfield, C.; Moussy, A.; Dubreuil, P.; Hermine, O.; Taieb, J. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S451 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 2355 Nab-paclitaxel plus gemcitabine or plus simplified LV5FU2 as first- line therapy in patients with metastatic pancreatic adenocarcinoma. A GERCOR randomized phase II study (AFUGEM). (September 2015) Authors: Bachet, J.B.; Hammel, P.; Desrame, J.; Chibaudel, B.; Debourdeau, P.; Dauba, J.; Lecomte, T.; Seitz, J.F.; Tournigand, C.; Aparicio, T.; Guerin Meyer, V.; Taieb, J.; Volet, J.; Bonnetain, F.; Louvet, C. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S453 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. 2376 Impact of the definition of time to event endpoint on randomized clinical trials results in oncology (datecan-2): an analysis of 9 pancreatic cancer trials. (September 2015) Authors: Pam, A.; Vernerey, D.; Baron, B.; Chauffert, B.; Louvet, C.; Wagener, J.; Levi, F.; Hans, S.; Trouilloud, I.; Jan, J.; Van Laethem, J.L.; Taieb, J.; Haustermans, K.; Dahan, L.; Dureux, M.; Lutz, M.; Bellera, C.; Gourgou, S.; Anota, A.; Bonnetain, F. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S462 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. 609TiPPRODIGE 50 - ASPIK French: French double blind randomised study of aspirin versus placebo in resected stage III or high risk stage II colon cancer with PIK3CA mutation. (18th September 2017) Authors: Michel, P.; André, T.; Boige, V.; Aparicio, T.; Maillard, E.; Bez, J.; Blot, J.; Bachet, J-B.; Dahan, L.; Guimbaud, R.; Manfredi, S.; Tougeron, D.; Taieb, J.; Selves, J.; Lepage, C.; Di Fiore, F. Journal: Annals of oncology Issue: Volume 28(2017)Supplement 5 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. FOLFIRINOX as induction treatment in rectal cancer patients with synchronous metastases: Results of the FFCD 1102 phase II trial. (November 2018) Authors: Dahan, L.; Auby, D.; Khemissa, F.; Ghiringhelli, F.; Nguyen, S.; Bedjaoui, A.; Terrebonne, E.; Thaury, J.; Baconnier, M.; Bachet, J.B.; Lucidarme, O.; Levache, C.B.; Barbier, E.; Raoul, J.L.; Lecomte, T.; Desauw, C.; Brocard, F.; Pernot, S.; Breysacher, G.; Lagasse, J.P. Journal: European journal of cancer Issue: Volume 104(2018) Page Start: 108 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Geriatric analysis from PRODIGE 20 randomized phase II trial evaluating bevacizumab + chemotherapy versus chemotherapy alone in older patients with untreated metastatic colorectal cancer. (July 2018) Authors: Zawadi, Mohamed-Ayman; Volet, Julien; Cavaglione, Gérard; Lepere, Céline; Rougier, Philippe; Zaanan, Aziz; Besson, Dominique; Fawzi, Kara Slimane; Adenis, Antoine; Gatineau-Sailliant, Gilles; Brezault, Catherine; Coriat, Romain; Tougeron, David; Hautefeuille, Vincent; Chone, Laurence; Molin, Yann... Journal: European journal of cancer Issue: Volume 97(2018) Page Start: 16 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Low-level postoperative carcinoembryonic antigen improves survival outcomes stratification in patients with stage II colon cancer treated with standard adjuvant treatments. (July 2018) Authors: Auclin, E.; André, T.; Taieb, J.; Benetkiewicz, M.; de Gramont, A.; Vernerey, D. Journal: European journal of cancer Issue: Volume 97(2018) Page Start: 55 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗